KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
DRP-104 Sensitive: B - Late Trials
|
DRP-104 Sensitive: B - Late Trials
|
KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
durvalumab Resistant: B - Late Trials
|
durvalumab Resistant: B - Late Trials
|
KEAP1 mutation
|
Solid Tumor
|
KEAP1 mutation
|
Solid Tumor
|
IPN60090 Sensitive: C2 – Inclusion Criteria
|
IPN60090 Sensitive: C2 – Inclusion Criteria
|
KEAP1 mutation
|
Lung Non-Small Cell Squamous Cancer
|
KEAP1 mutation
|
Lung Non-Small Cell Squamous Cancer
|
CB-228 Sensitive: C2 – Inclusion Criteria
|
CB-228 Sensitive: C2 – Inclusion Criteria
|
KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
docetaxel Resistant: C3 – Early Trials
|
docetaxel Resistant: C3 – Early Trials
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
KEAP1 mutation
|
LUAD
|
KEAP1 mutation
|
LUAD
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
KEAP1 mutation
|
LUAD
|
KEAP1 mutation
|
LUAD
|
DRP-104 Sensitive: D – Preclinical
|
DRP-104 Sensitive: D – Preclinical
|
KEAP1 mutation
|
Lung Cancer
|
KEAP1 mutation
|
Lung Cancer
|
IPN60090 Sensitive: D – Preclinical
|
IPN60090 Sensitive: D – Preclinical
|